Metabolic correction of dyslipidemia in patients with nonalcoholic fatty liver disease as a new therapy policy

  • Authors: Stel'makh VV1, Kozlov VK1,2,3
  • Affiliations:
    1. Северо-Западный государственный медицинский университет им. И.И. Мечникова
    2. Институт высоких медицинских технологий, Санкт-Петербург
    3. Университет им. Ярослава Мудрого, В. Новгород
  • Issue: Vol 85, No 4 (2013)
  • Pages: 71-76
  • Section: Editorial
  • URL: https://journals.rcsi.science/0040-3660/article/view/31253
  • ID: 31253

Cite item

Full Text

Abstract

AIM: To study the impact of infusion therapy with the metabolic modulator remaxol on lipid metabolic parameters and target organ (liver, kidney) function in metabolic syndrome (MS)/MATERIAL AND METHODS: The investigation enrolled 90 patients (54 men and 36 women) with primary nonalcoholic steatohepatitis that was associated with insulin-resistance and MS; their age was 21 to 77 years. Every day the study group patients (n=50) took as a component of combination therapy the metabolic hepatoprotective modulator remaxol intravenously in a dropwise manner in a dose of 400 ml once daily; the comparison group patients (n=40) received ademetionine 400 mg diluted in 400 ml of isotonic sodium chloride. The duration of infusion therapy was 11 days/RESULTS: Infusion therapy with remaxol caused a pronounced blood lipid composition-regulating effect, by reducing the level of major atherogenic lipids (total cholesterol, triglycerides) and improving liver function and renal nitrogen-excreting and filtration function in patients with Stage IV diabetic nephropathy in the presence of MS/CONCLUSION: Therapy with the metabolic hepatoprotective modulator remaxol ensures reliable metabolic control and multifactorial correction of risk factors of organ lesions in MS: cardio-, hepato-, and nephroprotection.

About the authors

V V Stel'makh

Северо-Западный государственный медицинский университет им. И.И. Мечникова

V K Kozlov

Северо-Западный государственный медицинский университет им. И.И. Мечникова; Институт высоких медицинских технологий, Санкт-Петербург; Университет им. Ярослава Мудрого, В. Новгород

References

  1. Belentani S., Scaglioni F., Marino M. et al. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010; 28: 155-161.
  2. Dixon J.B., Bhathal P.S., O'Brien P.E. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001; 121: 91-100.
  3. Guzman G., Brunt E.M., Petrovic L.M. et al. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008; 132: 1761-1766.
  4. Caldwell S., Argo C. The natural history of nonalcoholic fatty liver disease. Dig Dis 2010; 28: 162-168.
  5. Marchesini G., Bugianesi E., Forlani G. et al. Nonalcoholic fatty liver, steatohepatitis and the metabolic syndrome. Hepatology 2003; 37: 917-923.
  6. Belentani S., Marino M. Epidemiology and natural history of nonalcoholic fatty liver disease (NAFLD). Ann Hepatol 2009; 8 (suppl. 1): S4-S8.
  7. Ong J.P., Pitts A., Younossi Z.M. Increased overall mortality and liver-related mortality in nonalcoholic fatty liver disease. J Hepatol 2008; 49: 608-612.
  8. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000; 21 (3): 49-98.
  9. Буеверов А.О. Жирная печень: причины и последствия. Практикующий врач 2002; 1: 36-38.
  10. Fraze E., Donner C.C., Swislocki A.L. et al. Ambient plasma free fatty acid concentration in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrin Metab 1985; 61 (5): 807-811.
  11. Балаболкин М.И. Диабетология. М: Медицина 2000.
  12. Мамедов М.Н. Особенности липидных нарушений у больных сахарным диабетом 2-го типа: в каких случаях следует применять статины? Кардиология 2006; 3: 90-95.
  13. Костин В.И., Карпов В.С. Качество жизни пациентов с кардиальным синдромом Х. Клин мед 2001; 1: 25-27.
  14. Сholesterol Treatment Trialists (CTT) Colaboration. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials. Lancet 2010; 376: 1670-1681.
  15. Reiner Z., Catapano A.L., De Backer G. et al. ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the Europpean Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 2011; 32 (14): 1769-1818.
  16. Стельмах В.В., Козлов В.К., Радченко В.Г., Некрасова А.С. Патогенетическая терапия метаболического синдрома на стадии органных поражений. Клин мед 2012; 7: 35-41.
  17. Сологуб Т.В., Горячева Л.Г., Суханов Д.С. и др. Гепатопротективная активность ремаксола при хронических поражениях печени. Клин мед 2010; 1: 1-4.

Copyright (c) 2013 Consilium Medicum

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
 
 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies